|Number of pages||8|
|Journal||International Journal of Pharmacy and Pharmaceutical Sciences|
|Publication status||Published - 2010|
Access to Document
FingerprintDive into the research topics of 'Taste masking technologies: A review'. Together they form a unique fingerprint.
In: International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 2, No. 2, 2010, p. 6-13.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Taste masking technologies: A review
AU - Sharma, S.
AU - Lewis, S.
N1 - Cited By :39 Export Date: 10 November 2017 Correspondence Address: Lewis, S.; Dept of Pharmaceutics, Manipal college of Pharmaceutical Sciences, Manipal University, Manipal 576 104, Karnataka, India; email: email@example.com Chemicals/CAS: acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; ampicillin, 69-52-3, 69-53-4, 7177-48-2, 74083-13-9, 94586-58-0; cellulose acetate, 9004-35-7; chloroquine, 132-73-0, 3545-67-3, 50-63-5, 54-05-7; chlorpheniramine maleate, 113-92-8; ciprofloxacin, 85721-33-1; clarithromycin, 81103-11-9; dextromethorphan, 125-69-9, 125-71-3; ephedrine, 299-42-3, 50-98-6; erythromycin, 114-07-8, 70536-18-4; eucalyptus oil, 8000-48-4; eudragit, 24938-16-7, 51822-44-7, 9065-11-6; glycerol stearate, 11099-07-3, 31566-31-1, 8049-07-8; hydroxypropylmethylcellulose, 9004-65-3; ibuprofen, 15687-27-1; levofloxacin, 100986-85-4, 138199-71-0; metronidazole, 39322-38-8, 443-48-1; nizatidine, 76963-41-2; orbifloxacin, 113617-63-3; paracetamol, 103-90-2; paroxetine, 61869-08-7; ranitidine, 66357-35-5, 66357-59-3; roxithromycin, 80214-83-1; sildenafil, 139755-83-2; theophylline, 58-55-9, 5967-84-0, 8055-07-0, 8061-56-1, 99007-19-9; thymol, 89-83-8; triclosan, 3380-34-5; zinc acetate, 557-34-6 References: www.foodiesite.com/articles/2000-11/cheese.jsp; www.umds.ac.vk/physiology/jimtasteolf.htm; www.cf.ac.vk.biosi/staft/jacob/teaching/sensoy/taste.htm; Gyton, C., The chemical senses-Taste and smell (1986) Textbook of Medical Physiology, p. 745. , 7th ed. Hong Kong: W.B. Saunders Company; www.fda.com; Hussain, M.M., Barcelon, S.A., (1991) Flavor Enhancing and Medicinal Taste Masking Agent, , U.S. Pat. No. 4,983,394 to Warner- Lambert Co; Chase, G.D., Gennaro, A.R., Gibson, M.R., Pharmaceutical Necessities (1980) Remington's Pharmaceutial Sciences, pp. 1229-1231. , 16th ed. Pennsylvania: Mackpublishing company; Lachman, L., Lieberman, H.A., Kanig, J.L., Liquids (1987) The Theory and Practice of Industrial Pharmacy, 419, p. 470. , Pheladelphia: Lea and Febiger; Fuisz, R.C., (1991) Taste Masking of Pharmaceutical Floss With Phenol, , U.S. Pat. No. 5,028,632 to Fuisz pharmaceutical Ltd; Chewable Tablets (1981) Pharmaceutical Dosage Forms, 1, pp. 387-391. , Lieberman H.A., Lachman L. (Eds.), (Tablet). New York: Marcel Dekker Inc; Delhi, S., Patricia, A., (2001) Taste Masking of Phenolics Using Citrus Flavors, , U.S. Pat. No. 6,235,267 to Pfizer Inc; Depalmo, G.A., Taste masked oral compositions containing ibuprofen (1993) Eur. Pat. Appl, , EP 05,60,207 to Aziende chemiche Riunite Angelini Francesco (ACRAF) S.P.A; Dhiraj, S., (1998) Pediatric Ibuprofen Composition, , U.S. Pat. No. 4,788,220 to American Home Products Corporation; Eby III, G.A., (1992) Taste Masked Zinc Acetate Compositions For Oral Absorption, , U.S. Pat. No. 5,095,035; Augello, M., (2000) Croscarmellose Taste Masking, , U.S. Pat. No. 6,099,865 to FMC corporation; Bhardwaj, S., (1996) Palatable Pharmaceutical Compositions, , U.S. Pat. No. 5,578,316 to Smithkline Beecham Corporation; Pollinger, N., (2000) Flavor Masked Pharmaceutical Compositions, , U.S. Pat. No. 6,136,347 to Bayer Aktiengesellschaft; Danny, Y.U., Taste masked pharmaceutical liquid formulations (2001) PCT Int. Appl, , WO 01/03698 to Johnson and Johnson; Iton, A., No (2001) 6,221,402 to Pfizer Inc, , Rapidly releasing and taste masking pharmaceutical dosage form. U.S. Pat; Alkire, T.G., No (1997) 5,607,697 to Cima Labs, , Taste masking microparticles for oral dosage forms, U.S. Pat; Hoy, M.R., (1996) Taste Masked Coating For Preparation of Chewable Pharmaceutical Tablets, , U.S. Pat. No. 5,489,436 to Mcheil-PPC Inc; Ventourar, K., (1989) Swellable Pellets, , U.S. Pat. No. 4,882,169 to Zyma Sa; Seager, H., (1977) Pharmaceutical Formulations, , U.S. Pat. No. 4,016,254 to Beecham Group Limited; Cumming, K.I., (2000) Taste Masked Formulations, , U.S. Pat. No. 6,153,220 to Elan corporation PLC; Morella, A.M., (2001) Taste Masked Liquid Suspensions, , U.S. Pat. No. 6,197,348 to FH Faulding and co. Limited; Yojima, T., Nogata, A., Particle design for taste masking using spray-congealing technique (1996) Chem Pharm. Bull, 44, pp. 187-191; Ndesendo, V.M.K., Meixner, W., Microencapsulation of chloroquine diphosphate by Eudragit RS.100 (1996) J. Microencap, 13, pp. 1-8; Mauger, J.W., Robinson, D.H., (1998) Coating Technology For Taste Masking Orally Administered Bitter Drugs, , U.S. Pat. No 5,728,403 to university of the braska; Wurster, D.E., (1981) Particle Coating Method, p. 119. , In Pharmaceutical Dosage Form.New York: Marcel Dekker Inc; Habib, Y.S., Shangraw, R., (1998) Cushioning Beads and Tablet Comprising the Same Capable of Forming a Suspension, , U.S. Pat. No. 5,780,055 to University at Maryland, Baltmore; Mehta, A.M., (1989) Taste Masked Pharmaceutical Composition, , U.S. Pat. No. 4,800,087; Friend, D.R., Ng, S., (2000) Taste Masked Microcapsule Composition and Methods of Manufacture, , U.S. Pat. No. 6,139,865 to Eurand America Inc; Dauglas, S.I., (1997) Taste Masking Compositions of Ranitidine, , U.S. Pat. No. 5,635,200 to Glaxo Group ltd; (1980) Ion Exchange Resin In Microencapsulation, p. 150. , Deasy, Newyork: Marcel Dekker Inc; Reynold, E.V., Ion exchange resin (1982) Martindale the Extra Pharmacopoeia, p. 869. , 28th Edition. London: Pharmaceutical Press; Swarbrick, J., Boylon, S.C., (1990) Ion Exchange Resin. In Encylopedia of Pharmaceutical Technology, 8, pp. 203-216. , New York: Marcel Dekker Inc; Cristal, M., Particle Application of ion exchange resins (1985) Manuf. Chem, 56, pp. 50-53; Denney, R.C., Jeffery, G.H., Ion exchange (1978) Vogel's Textbook of Quantitative Inorganic Analysis, pp. 165-172. , 4th edition. England: Longman scientific and Technical; Eichman, M.L., (1999) Drug Resin Complexes Stabilized By Chelating Agents, , U.S. Pat. No. 5,980,882 to Medeva Pharm. Manuf; Motyoka, S., Nairn, J.G., Influence of coating on release rate of anion from ion exchange resins beads (1978) J. Pharm. Sci, 67, pp. 500-503; Wen, B., Ramsay, M.P., (1999) Antitussive Drugs Delivered By Ion Exchange Resins, , U.S. Pat. No. 6,001,392 to Warner-Lambert Company; Borodkin, S., (1976) Iron-resin Adsorbate, , U.S. Pat. No. 3,947,572 to Abbott Laboratories; Raghunathan, Y., (1980) Prolonged Release Pharmaceutical Preparations, , U.S. Pat. No. 4,221,778 to Pennewalt Corp; Sheumaker, J.L., (1988) Liquid Prolonged Release Pharmaceutical Formulations Containing Ionic Constituents, , U.S. Pat. No. 4,762,709 to Pennewalt Corp; Agarwal, R., Mital, R., Studies of ion exchange resin complex of chloroquine phosphate (2000) Drug Dev. Ind. Pharm, 26, pp. 773-776; Lang, P.M., (1992) Preparation and Use of Ion Exchange Resin Loaded With Quinolone Carboxylic Acid Derivatives, , U.S. Pat. No. 5,152,986 to Bayer Aktiengesellschaft; Louis, M., Cliflon, N.S., (1967) D-methorphan Compositions and Method of Making Same, , U.S. Pat. No. 3,346,449 to Roche Inc; Manek, S.P., Kamath, V.S., Evaluation of Indion CRP 244 and CRP 254 as sustained release and taste masking agents (1981) Indian J. Pharm. Sci, 43, pp. 209-212; Ly, M.F., Borodkin, S., (1989) Antibiotic Polymer Compositions, , U.S. Pat. No. 4,808,411 to Abbott Laboratories; Lv, M.F., Borodkin, S., A polymer carrier System for taste masking of macrolide antibiotics (1991) Pharm. Res, 8, pp. 706-712; Gao, R., Taste masking of oral quinolone liquid preparations using ion exchange resins (2001) PCT Int. Appl, , Wo 01/05431 to Schering-Plough Ltd; Leonard, G.S., Cooper, D., (1998) Oral Liquid Compositions Containing Paroxetine Resinate, , U.S. Pat. No. 5,811,436 to Smithkline Beecham Plc; Douglas, S.J., Bird, F.R., (1991) Drug Adsorbates, , U.S. Pat. No. 5,032,393 to Glaxo group Ltd; Metcalf, S., Purdy, K., (2001) Pharmaceutical Formulation Comprising a 2-aminoacetamide Derivative and An Ion Exchange Resins, , U.S. Pat. No. 6,193,962 to Astrazeneca U.K. Ltd; Borodkin, S., Yunker, M.H., Interaction of amine drugs with a polycarboxylic acid ion exchange resins (1970) J. Pharm. Sci, 59, pp. 481-486; (1990) Chewable Tablets In Encyclopedia of Pharmaceutical Technology, 2, pp. 400-402. , Swarbrick, J., Boylan, S.c. (eds), New York: Marcel Dekker Inc; Roy, G.M., Taste masking in oral pharmaceuticals (1994) Pharm. Tech, 18, pp. 84-99; Fulzele, S.V., Jaiswal, S.B., Preliminery studies on the development of new non-bitter chloroquine formation using tannic acid (2001) Indian J. Pharm. Sci, 63, pp. 45-48; Tsau, J.H., Damani, N.C., (1990) Taste Masking Compositions, , U.S. Pat. No. 4,971, 791 to The Procter and Gamble Company; Appelgren, C., Eskilson, C., A novel method for the granulation and coating of pharmacologically active substances (1990) Drug Dev. Ind. Pharm, 16, pp. 2345-2351; Ishikawa, T., Watanbe, Y., Preparation and evaluation of tablets rapidly disintegrating in saliva containing bitter taste masked granules by the compression method (1999) Chem. Pharm. Bull, 47, pp. 1451-1454; Mackles, L., Chavkin, L., (1998) Tasteless Forms of Basic Drugs Prepared By Absorption In Situ, , U.S. Pat. No. 5, 811, 131 to Behr Esg; Hussain, M.A., August, B.J., Improved buccal delivery of opioid analgesics and antiagonists with bitterless prodrugs (1988) Pharm. Res, 5, pp. 615-618; Taylor, E.P., A tasteless derivative of chloramphenicol (1953) J. Pharm. Pharmacol, 5, pp. 254-256; Sinkula, A.A., Yalkowsky, S.H., Rationale for design of biologically reversible drug derivatives (1975) J. Pharm. Sci, 64, pp. 200-203; Brahamnkar, D.M., Jaiswal, S.B., Prodrugs (1998) Biopharmaceutics and Pharmacokinetics; a Treatise, pp. p163. , Vallabh Prakashan. Delhi; Russel, S.J., Paul, A.S., Suppression of bitterness using sodium salts (2001) Flavours and Fragrances, 55, pp. 441-447; Breshlin, P.A.S., Beauchamp, G.K., Suppression of bitterness by sodium variation among bitter taste stimuli (1995) Chemical Senses, 20, pp. 609-623; Katsuragi, Y., Sugiura, Y., Selective nhibition of bitter taste of various drugs by lipoprotein (1995) Pharm. Res, 12, pp. 658-662; Katsurgi, Y., Yasumasu, T., Lipoprotein that selectively inhibits taste nerve responses to bitter substances (1996) Brain Res, 713, pp. 240-245; Katsurgi, Y., Kashiwayanagi, M., Specific inhibitor for bitter taste inhibition of taste nerve responses and human taste sensation to bitter stimuli (1997) Brain Res Protocols, 1, pp. 292-298; Katsurgi, Y., Mitsui, Y., Basic studies for the practical use of bitterness inhibitors (1997) Pharm. Res, 14, pp. 720-724; Saito, M., Masahiro, H., The marked inhibitions of the bitter taste of Polymixin B sulfate and Trimethoprim- Sulfamethoxazole by flavored BMI 60 in padiatric patients (1999) Biol. Pharm. Bull, 22, pp. 997-998; Rao, M.Y., Bader, F., Masking the taste of chloroquine by preparing multiple emulsions (1991) The Eastern Pharmacists, pp. 123-124. , November; Vazliri, A., Warburton, B., Slow release of chloroquine phosphate from multiple taste masked w/o/w multiple emulsion (1994) J. Microencap, 11, pp. 641-648; Kaning, K., Kanada, K., Application of gel formation for taste masking (1997) Chem. Pharm. Bull, 45, pp. 1063-1068; Niazi, S., Shamesh, A., (1987) Chewing Gum Containing a Medicament and Taste Maskers, , US Patent 04,639,368; January 27; Pather, S.I., Khankari, R.K., Eichman, J.D., Robinson, J.R., Hontz, J., (2002) Sublingual Buccal Effervescent, , US Patent 20,020,110,578: August 15; Blasé, C.M., Shah, M.N., Taste masked pharmaceutical suspensions for pharmaceutical actives (1993) Eur. Pat. Appl, , EP0556057; August 18; Skraanga, A.T.P., Tully, R.E., (2000) Oral Liquid Antidepressant Ssolution, , U.S. Patent 6,040,301; March 31; (1990) Flavors and Flavors Modifier. In Encyclopedia of Pharmaceutical Technology, 6, pp. 117-137. , Swarbrik, J., Boylan, S.C. (Eds.), New York: Marcel Dekker Inc; Takagi, S., Toka, K., Detection of suppression of bitterness by sweet substance using a multichannel taste sensor (1998) J. Pharm. Sci, 87, pp. 552-555; Uchida, T., Miyanaga, Y., Quantitative evaluation of the bitterness of commercial medicines using a taste sensor (2000) Chem. Pharm. Bull, 48, pp. 1843-1845; Shirai, Y., Sogo, K., A novel fine granules system for masking bitter taste (1993) Biol. Pharm. Bull, 16, pp. 172-177
PY - 2010
Y1 - 2010
N2 - Oral administration of pharmaceuticals is one of the most popular method of drug dilevery. Many orally administered drugs elicit bitter taste. Palatability is an extremly important factor in ensuring the likelihood that the recepient will intake the pharmaceuticals. A constant problem is in treatment of patient is their inability or unwillingness to swallow solid dosage form such as tablets specially in children and the elderly. These dosage form permit perceptible exposure of active drug ingredient to the taste bud. Accordingly, masking of unpleasent taste characterstics of drug is an important factor in formulation of these agents."The worse the taste of the medication, the better the cure" was once the prevailing attitude. Today a change in patient attitude and development of taste masking technique has reversed this opinion. Patients now expect and demand formulations that are pleasently, or atleast tolerably, flavored.1 This article reviews the earlier methodologies and approaches of taste masking of bitterness reduction.
AB - Oral administration of pharmaceuticals is one of the most popular method of drug dilevery. Many orally administered drugs elicit bitter taste. Palatability is an extremly important factor in ensuring the likelihood that the recepient will intake the pharmaceuticals. A constant problem is in treatment of patient is their inability or unwillingness to swallow solid dosage form such as tablets specially in children and the elderly. These dosage form permit perceptible exposure of active drug ingredient to the taste bud. Accordingly, masking of unpleasent taste characterstics of drug is an important factor in formulation of these agents."The worse the taste of the medication, the better the cure" was once the prevailing attitude. Today a change in patient attitude and development of taste masking technique has reversed this opinion. Patients now expect and demand formulations that are pleasently, or atleast tolerably, flavored.1 This article reviews the earlier methodologies and approaches of taste masking of bitterness reduction.
M3 - Article
SN - 0975-1491
VL - 2
SP - 6
EP - 13
JO - International Journal of Pharmacy and Pharmaceutical Sciences
JF - International Journal of Pharmacy and Pharmaceutical Sciences
IS - 2